mRNA-5671
| Vaccine description | |
|---|---|
| Target | Cancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene |
| Vaccine type | mRNA |
| Clinical data | |
| Routes of administration | Intramuscular |
mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna.[1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene.[2] It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.[3]
In 2021 Merck dropped the trial,[4][5] and clinicaltrials.gov study NCT03948763 ended 2022-08-25.[6] As of May 2024, no further progress on this vaccine has been announced.
References[edit]
- ^ "mRNA 5671". AdisInsight. Springer Nature Switzerland AG.
- ^ "mRNA-derived KRAS-targeted vaccine V941". National Cancer Institute Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.
- ^ Clinical trial number NCT03948763 for "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)" at ClinicalTrials.gov
- ^ https://www.fiercebiotech.com/biotech/merck-cuts-ties-modernas-early-phase-kras-vaccine-leaving-mrna-specialist-mull-next-steps
- ^ "Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates".
- ^ "A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma". 5 September 2022.
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |